Cancer Targeted Technology
14241 NE Woodinville-Duvall Road #143
4 articles with Cancer Targeted Technology
Cancer Targeted Technology Commences Phase I Clinical Trial in Prostate Cancer Patients with an Innovative Radiotherapy, CTT1403, and Receives a $3.2M NIH Grant to Fund the Trial
The clinical trial is being conducted at University of California, San Francisco in collaboration with Dr. Rahul Aggarwal as Principal Investigator.
Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced today that it filed an Investigational New Drug Application (IND) with the FDA to move forward a radiotherapeutic drug, CTT1403, into human clinical trials for prostate cancer.
Small Business Innovation Research (SBIR) grant to develop CTT1700, a unique prodrug targeted at men with prostate cancer that express Prostate Specific Membrane Antigen (PSMA).
Advanced Accelerator Applications Signs Exclusive License Agreement With Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
The terms of the agreement include an upfront licensing fee, as well as certain milestone and royalty payments.